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ABSTRACT 
Objective: In the present investigation efforts were considered to optimize the different conditions for the preparation of spray dried lactose based 
proniosomes. The aim of this research was to investigate the feasibility of proniosomes as stable precursors for the development of niosomes as oral 
drug delivery system for poorly water-soluble drugs. 
Methods: A total of twenty-eight plain proniosomal formulae were prepared with various surfactant-cholesterol loading ratios in each formula 
using spray dried lactose as a carrier. Span 20, 40, 60 and 80 were used in various molar ratios with cholesterol. Different evaluation techniques 
were performed to study the performance of the prepared proniosomes. The micromeritic properties of the prepared proniosomes were analyzed. 
The reconstituted niosomes were further evaluated for morphological characterization using transmission electron microscope (TEM), particle size 
analysis, zeta potential, and polydispersity index (PDI). Finally, selected proniosomal formulae were tested for stability study.  
Results: The proniosomal formulae prepared using span 40 and span 60 exhibited excellent flowability while those prepared with span 20 and span 
80 showed poor flow properties. TEM photographs revealed that the vesicles were discrete, spherical without aggregation. The mean vesicle size of 
reconstituted niosomes was found to be in the range between (252.9±0.43–624.3±0.23 nm) with perfect PDI values (0.387±0.05–0.835±0.03). The 
negative values of zeta potential indicated that all prepared formulae were stabilized by electrostatic repulsion forces. Stability studies confirmed 
that proniosomes give a more stable system that could overcome the problems of standard niosomes. Formulae with the smallest particle size, 
higher surface charge values and best flow properties were selected to be loaded with poorly soluble drugs for further study. 
Conclusion: The obtained results offered evidence that spray-dried lactose based proniosomes are promising stable drug delivery carriers and 
ready to incorporate various poorly water-soluble drugs in order to improve their limited oral bioavailability. 
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Over the decades, the oral route remains the most preferred route of 
administration for drug delivery. However, a plurality of the new 
and present drugs taken by oral route usually face bioavailability 
drawbacks [1]. Different approaches have been employed for 
improving the dissolution profile of poorly water-soluble drugs [2].  
Considerable interest has been focused on the design and 
formulation of new drug delivery systems. Among them, vesicular 
drug delivery systems are of high significance. There are different 
types of vesicular drug delivery systems such as liposomes, 
niosomes, transferosomes, ethosomes, colloidosomes, and 
cubosomes. Novel approaches like provesicular drug delivery 
systems such as proniosomes, layerosomes and ufosomes have also 
been developed which have higher stabilities compared to 
conventional and simple vesicular systems [3]. Provesicular systems 
can be used for prolonged and targeted drug delivery with mild side 
effects and also provides patient compliance by decreasing the 
administered dose. 
Colloidal particulate drug delivery systems such as liposomes [4] or 
niosomes [5] are very distinguished in comparison to conventional 
dosage forms because these vesicular systems can act as drug-
containing reservoirs and alter the particle composition or surface 
to adjust the drug release or the affinity of the drug for the target 
site. Niosomes are nonionic surfactant vesicles which can entrap 
both hydrophilic and hydrophobic drugs [6]. Niosomes proved to be 
an alternative to liposomes because they have more chemical 
stability and economical as compared to liposomes. But though 
niosomes reveal good chemical stability, there may be drawbacks of 
physical instability concerning the dispersions. Similar to liposomes, 
aqueous niosomal dispersions may show aggregation, fusion, 
leakage of included drugs, or hydrolysis of encapsulated drugs, thus 
reducing the shelf life of niosomes [7]. 
So as to overcome the stability troubles concerning niosomes, 
proniosomes (dry niosomes) were developed. Proniosomes are 
dried powder, free flowable, granular product which upon dilution 
with water develops niosomal dispersion convenient for oral 
administration [8]. The niosomes formed after reconstitution is 
analogous to conventional niosomes, however, have uniform size [9]. 
Different nonionic surfactants with varying HLB were used in the 
preparation of proniosomes such as polyoxyethylene sorbitan esters 
(Tweens) [10], polyoxyethylene alkyl ethers (Brijs) and sorbitan 
esters (spans) [11]. It was noticed that for optimum proniosomes 
formulations which achieved smaller particle size, and higher 
entrapment efficiency is obtained within the HLB range from 1 to 8, 
which is the range of spans [12]. Cholesterol provides rigidity to the 
niosomes after the hydration of proniosomes and decreases drug 
leakage, thus increasing the entrapment efficiency. It also stabilizes 
the structure of the niosomes by inhibition of aggregate formation 
by exerting steric effect [13].  
Different carriers are used in the formation of the dry proniosomes 
such as: mannitol, sorbitol, lactose and maltodextrin. The desired 
properties of the carrier include; non-toxicity and in vivo safety, poor 
solubility in the solvent of the loaded solution, free flowability, and 
excellent water solubility for easy and instant hydration [14]. Spray 
dried lactose shows optimum behavior as a carrier in proniosomal 
systems as it has a spherical shape and best flowability among other 
carriers [15]. 
There are the various method used for the preparation of 
proniosomes which include a slurry method and the spraying of 
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surfactant on solid carrier [16]. There are several factors that must 
be controlled for the successful formulation of proniosomes. Among 
the factors, the concentration of surfactant, the ratio of surfactant 
concentration to cholesterol concentration, the type of the solid 
carrier and other factors related to the preparation technique such 
as the amount of organic solvent and the speed of stirring [17]. 
This research is a screening study aims to prepare plain (unloaded) 
proniosomes with optimized composition. Factors studied are the 
surfactant type and the ratio of surfactant to cholesterol. The 
selection of the optimum proniosomal formula allows a better 
understanding of the factors that governs the characteristics of the 
formed niosomes that can be loaded with different drugs. The aim of 
our work was to assure the feasibility of proniosomes as stable 
precursors for the development of niosomes as oral drug delivery 
system for drugs with low oral bioavailability.  
MATERIALS AND METHODS 
Materials 
Cholesterol was purchased from Panreac Quimica SA, Barceolna, 
Spain. Span 40 (Sorbitan monopalmitate), Span 60 (Sorbitan 
monostearate) and Sodium Hydroxide were purchased from Oxford 
Laboratory Chemicals, India. Span 20 (Sorbitan monolaurate) and 
Span 80 (Sorbitan monooleate) were from Kermel, Chemical Pure, 
China. Methanol and Chloroform were purchased from Fisons 
Scientific Equipment, England. Spray Dried Lactose was kindly 
supplied as a gift sample from Medical Union Pharmaceuticals, 
Egypt. Sodium Dihydrogen Phosphate was obtained from PureLab, 
USA. All other chemicals used were of analytical grade. 
Methods 
Preparation of dry granular proniosomes 
Dry Proniosomes were prepared using the slurry method [18]. The 
composition of various proniosomal formulae is shown in the table 
(1). Shortly, precisely weighed amounts of lipid mixture (300 μmol) 
consisting of different grades of spans (20, 40, 60 and 80) and 
cholesterol at different molar ratios (3:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2 
and 1:3 respectively) were dissolved in 10 ml of solvent mixture 
containing chloroform and methanol (7:3 ratio). This solution was 
transferred into a 100 ml round bottomed flask and spray dried 
lactose (1.5 gm) was added to form slurry [19]. The flask was 
attached to a rotary evaporator (Heidolph, Germany) and the solvent 
mixture was evaporated under pressure of 600 mmHg at a 
temperature of 45±2 °C and 60 rpm until spray dried lactose 
appeared to be dry as a thin powder film on the flask wall [20]. After 
ensuring the complete removal of solvent, the resultant powder was 
scraped and collected. The proniosomal powder was further dried 
overnight in desiccators at room temperature to obtain dry, free-
flowing product. The obtained proniosomal powders were stored in 
a tightly closed container for further characterization. 
 
Table 1: Compositions of various spray-dried lactose based proniosomal formulae 
Formula Surfactant Surfactant: cholesterol Ratio (µmol) Spray dried lactose (mg)* 
F1 Span 20 3:1 225:75 300 
F2 Span 20 2:1 200:100 300 
F3 Span 20 1.5:1 180:120 300 
F4 Span 20 1:1 150:150 300 
F5 Span 20 1:1.5 120:180 300 
F6 Span 20 1:2 100:200 300 
F7 Span 20 1:3 75:225 300 
F8 Span 40 3:1 225:75 300 
F9 Span 40 2:1 200:100 300 
F10 Span 40 1.5:1 180:120 300 
F11 Span 40 1:1 150:150 300 
F12 Span 40 1:1.5 120:180 300 
F13 Span 40 1:2 100:200 300 
F14 Span 40 1:3 75:225 300 
F15 Span 60 3:1 225:75 300 
F16 Span 60 2:1 200:100 300 
F17 Span 60 1.5:1 180:120 300 
F18 Span 60 1:1 150:150 300 
F19 Span 60 1:1.5 120:180 300 
F20 Span 60 1:2 100:200 300 
F21 Span 60 1:3 75:225 300 
F22 Span 80 3:1 225:75 300 
F23 Span 80 2:1 200:100 300 
F24 Span 80 1.5:1 180:120 300 
F25 Span 80 1:1 150:150 300 
F26 Span 80 1:1.5 120:180 300 
F27 Span 80 1:2 100:200 300 
F28 Span 80 1:3 75:225 300 
*One milligram of the carrier (spray dried lactose) per 1 μmol of total lipid surfactant mixture. 
 
Evaluation of the proniosomes and proniosome-derived niosomes 
Micromeritic properties of powdered proniosomes 
The angle of repose (θ) 
The angle of repose of powdered proniosomes was measured by the 
funnel method. Accurately weighed amount was poured through a 
funnel. The height of the funnel was adjusted accurately in a way 
that the tip of the funnel just touches the apex of proniosomes 
powder. The powder was then allowed to flow through the funnel. 
The radius of the powder pile was measured and the angle of repose 
determined using the following equation [21]: 
tan θ = h/r 
Where; h = height of the pile, r = radius of the pile 
Bulk and tapped density  
Two grams of powdered proniosomes was taken into a 10 ml 
measuring cylinder. Former volume was observed, and then the 
cylinder was allowed to fall under its own weight onto a hard flat 
surface from a height of 2.5 cm at 2-second intervals. The tapping 
was continued until no change in volume was remarked. Bulk and 
tapped densities were determined using the following equations 
[22]: 
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BD = Powder weight/Bulk Volume 
TD = Powder weight/Tapped Volume 
Compressibility index  
The compressibility of dry proniosomes was calculated by Carr’s 
Index as follow [23]: 
Carr’s Index (%) = [(TD-BD)/TD] X 100 
Hausner ratio  
It is the ratio of tapped to bulk density. It provides an idea about the 
flow properties of the powder and can be determined as follow [24]: 
Hausner ratio = TD/BD 
Preparation of niosomes from proniosomes and morphological 
evaluation (Photomicroscopy) 
Proniosomes were transformed to noisome by hydrating with 10 ml 
distilled water at 37 °C and gentle agitation using vortex mixer 
(MaxiMix II, USA) for 5 min. The formed niosomes were sonicated 
twice for 30 seconds using sonicator (SONICS VCX 130, USA) [25]. 
The niosomal dispersion was put on a glass slide, and the formed 
vesicles were observed at a magnification of 1000x through an 
optical microscope. The formation of vesicles was observed using an 
optical microscope and photomicrographs were recorded [26]. 
Morphological characterization using TEM 
The morphology of niosomal dispersion was observed using 
transmission electron microscopy (JEM-2100, USA). A drop of 
dispersion was cleaned with phosphate buffer pH 7.4 and put on 
carbon-coated 300 mesh copper grid and left for 1 minute to form a 
thin film. These films were then negatively stained with 2% (w/v) 
phosphotungstic acid solution. After drying with air, the stained 
films were photographed using TEM [27]. The experiment was 
performed at room temperature, and micrographs were taken at 
suitable magnification power. 
Analysis of the recorded TEM images 
The size distribution of the prepared proniosomes derived niosomes 
was analyzed using TEM images by the software Nano Measurer 
1.2.5 (Fudan University, Shangshai, China) [28]. 
Particle size analysis and PDI determination 
A small amount of freshly prepared proniosomes derived niosomes 
was used to determine the particle size and PDI. The vesicle size and 
PDI of the resultant niosomes were measured by dynamic light 
scattering (DLS) using a photon correlation spectrometer (Zetasizer, 
Malvern Instruments LTD, UK) which analyzes the fluctuations in 
light scattering due to the Brownian motion of the particles. Light 
scattering was monitored at 25 °C at a scattering angle of 90 ° [29]. 
Zeta potential determination 
Zeta potential was determined to measure the stability of 
reconstituted niosomes. The zeta potential of the formed niosomal 
dispersions was determined using Zetasizer (Malvern Instruments, 
UK). Samples were placed in clear disposable zeta cells, and results 
were noted. Charges on the vesicular surface and their 
corresponding zeta potential values were obtained [30].  
Stability studies 
Selected proniosomal formulae were examined for stability by 
storing them at 4 °C±1 (refrigeration temperature) and at 25 °C±2 
(room temperature) for a period of 3 mo [31]. At specific time 
intervals (0, 30, 60 and 90 d), samples were withdrawn and assessed 
for micromeritic properties, vesicles size and zeta potential [32].  
RESULTS AND DISCUSSION 
Evaluation of the proniosomes and proniosome-derived niosomes 
Micromeritic properties of powdered proniosomes 
Micromeritic properties of proniosomal formulae were considered 
as an important parameter as it will affect the uniformity of dose and 
facility of filling into capsules. The flow properties were evaluated 
with the aid of angle of repose, Carr’s index, and Hausner ratio. The 
angle of repose was found to affect the flowability of the particles. 
The values less than 20 ° exhibit excellent flowability; the values 
between 20 and 30 ° show good flowability; the values between 30 
and 34 ° exhibit passable flowability; while the values above 34 ° 
show very poor flowability [33]. Results obtained pointed out that 
proniosomal formulae containing span 20 [F1, F2, F3, F4, F5, F6 and 
F7] and span 80 [F22, F23, F24, F25, F26, F27 and F28] which are 
viscous liquid surfactants have large angle of repose (>30), 
promising poor flowability. The values obtained for the angle of 
repose for proniosomal formulae containing span 20 and span 80 
ranged from 32.02 °±0.81 to 41.87 °±1.50, as presented in table (2). 
These values suggest that all proniosomal formulae containing span 
20 and span 80 have passable to poor flowability. This may be due to 
powders cohesivity which affects the flow characteristics and 
occasionally causes difficulties in powder flow.
The optical photographs of all reconstituted proniosomal 
formulae are shown in fig. (1-28). The photographs revealed that 
the formed niosomes are unilamellar vesicles with a spherical 
shape and smooth surface. The vesicles were insular and 
separate without aggregation or lumping. Apparently, 
proniosomal formulae containing span 40 and span 60 yielded 
vesicles of large numbers with well-identified outline and core 
which will affect the entrapment efficiency of loaded drug 
directly. However proniosomal formulae containing span 20 and 
span 80 produced small numbers of vesicles with a slightly 
different outline. This may be due to the high phase transition 
temperatures of both span 40 and span 60 which will cause the 
formation of a large number of stable niosomal vesicles. The 
phase transition temperatures for span 20, 40 and 60 are 16, 42 
and 53 °C; respectively, however, span 80 possess the lowest 
phase transition temperature at 12 °C [35]. This explains why 
proniosomal formulae containing span 20 and span 80 produce 
small numbers of vesicles upon hydration. 
 On the other hand, 
proniosomal formulae containing span 40 [F8, F9, F10, F11, F12, F13 
and F14] and span 60 [F15, F16, F17, F18, F19, F20 and F21] which 
are solid surfactants have small angle of repose (<30), confirming 
good flow properties. The values obtained for the angle of repose for 
proniosomal formulae containing span 40 and span 60 ranged from 
24.79°±0.76 to 28.43°±1.30. These values indicate that all 
proniosomal formulae containing span 40 and span 60 have good 
flowability.  
The flow properties of the prepared proniosomal formulae were 
also characterized by determining both bulk and tapped 
densities. From these values, both the Hausner ratio and the 
Carr’s index can be derived. Both bulk and tapped densities were 
determined with equations described before in the experimental 
part. These two parameters are related to the flow properties of 
the prepared powder blend [34]. Carr’s index of proniosomal 
formulae is having span 20 and span 80 was found to be between 
21.00±1.32 and 31.38±2.39 indicating poor flowability. However, 
Carr’s index of proniosomal formulae containing span 40 and 
span 60 ranged between 11.07±2.76 and 19.62±2.50 which give 
confirmation about the good flow properties of these formulae. 
These findings were further shored by Hausner ratio values. The 
Hausner ratio results of proniosomal formulae having span 20 
and span 80 were found to be between 1.27±0.02 and 1.46±0.05 
indicating poor flowability. On the other hand, proniosomal 
formulae containing span 40 and span 60 have values of Hausner 
ratios between 1.13±0.04 and 1.24±0.04 assuring good flow 
properties. Finally, it was noticed that proniosomal formulae 
containing span 40 and span 60 have good flow properties. 
However, those having span 40 and span 60 show poor 
flowability. This may be due to cohesivity of powders imparted 
by viscous liquid span 20 and span 80. 
Preparation of niosomes from proniosomes and morphological 
evaluation (Photomicroscopy) 
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Table 2: Micromeritic properties of all prepared proniosomal formulae 
Formula Angle of repose* Bulk density* (g/ml) Tapped density* (g/ml) Carr’s index* (%) Hausner ratio* 
F1 41.87±1.50 0.5043±0.01 0.6250±0.01 21.00±1.32 1.27±0.02 
F2 36.89±1.17 0.5130±0.01 0.6452±0.03 22.23±1.60 1.29±0.03 
F3 39.82±1.18 0.5043±0.02 0.6897±0.01 26.05±1.30 1.35±0.02 
F4 36.20±0.57 0.5311±0.01 0.7407±0.02 27.43±1.36 1.38±0.03 
F5 36.87±0.60 0.5173±0.01 0.7143±0.01 25.84±2.27 1.35±0.04 
F6 33.99±0.52 0.5043±0.01 0.6897±0.01 25.19±2.22 1.34±0.04 
F7 32.02±0.81 0.5218±0.01 0.6897±0.01 26.07±2.27 1.35±0.04 
F8 28.43±1.30 0.4919±0.02 0.5714±0.01 13.11±1.33 1.15±0.02 
F9 28.20±0.97 0.5043±0.01 0.5882±0.01 12.61±0.19 1.14±0.01 
F10 27.17±1.01 0.5000±0.01 0.5882±0.02 15.00±2.50 1.18±0.03 
F11 26.21±0.86 0.4959±0.01 0.5714±0.01 12.38±2.32 1.14±0.03 
F12 27.77±0.62 0.5085±0.01 0.6061±0.01 16.94±1.37 1.20±0.02 
F13 25.13±0.80 0.5130±0.02 0.6452±0.01 19.62±2.50 1.24±0.04 
F14 26.01±0.55 0.4959±0.01 0.6061±0.02 14.88±2.51 1.18±0.03 
F15 26.39±0.86 0.4959±0.01 0.5882±0.01 16.50±2.61 1.20±0.04 
F16 27.16±0.60 0.5043±0.01 0.5882±0.01 15.94±2.70 1.19±0.04 
F17 25.12±0.59 0.5173±0.01 0.5714±0.01 11.18±2.84 1.13±0.04 
F18 28.20±0.97 0.4959±0.01 0.5714±0.01 12.38±2.32 1.14±0.03 
F19 25.87±1.36 0.5002±0.01 0.5882±0.02 14.98±2.36 1.18±0.03 
F20 24.79±0.76 0.5130±0.01 0.5714±0.01 11.07±2.76 1.13±0.03 
F21 26.21±0.86 0.4919±0.01 0.5882±0.01 18.03±1.30 1.22±0.02 
F22 39.08±1.76 0.4959±0.01 0.7143±0.02 31.38±2.39 1.46±0.05 
F23 39.42±0.66 0.5130±0.01 0.6897±0.01 26.49±0.94 1.36±0.02 
F24 37.58±1.07 0.5043±0.01 0.6897±0.03 30.26±2.54 1.44±0.05 
F25 34.02±1.38 0.5173±0.01 0.6897±0.01 24.13±1.34 1.32±0.02 
F26 36.54±1.01 0.5000±0.01 0.6667±0.01 23.33±1.44 1.30±0.02 
F27 34.92±1.07 0.5085±0.01 0.6250±0.02 21.15±1.57 1.27±0.06 
F28 35.25±1.44 0.5218±0.01 0.6897±0.01 24.34±1.13 1.32±0.02 
*Results are expressed as mean±S. D, n=3 
 
   
Fig. 1: Optical photograph of F1 Fig. 2: Optical photograph of F2 Fig. 3: Optical photograph of F3 
   
Fig. 4: Optical photograph of F4 Fig. 5: Optical photograph of F5 Fig. 6: Optical photograph of F6 
   
Fig. 7: Optical photograph of F7 Fig. 8: Optical photograph of F8 Fig. 9: Optical photograph of F9 
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Fig. 10: Optical photograph of F10 Fig. 11: Optical photograph of F11 Fig. 12: Optical photograph of F12 
   
Fig. 13: Optical photograph of F13 Fig. 14: Optical photograph of F14 Fig. 15: Optical photograph of F15 
   
Fig. 16: Optical photograph of F16 Fig. 17: Optical photograph of F17 Fig. 18: Optical photograph of F18 
   
Fig. 19: Optical photograph of F19 Fig. 20: Optical photograph of F20 Fig. 21: Optical photograph of F21 
   
Fig. 22: Optical photograph of F22 Fig. 23: Optical photograph of F23 Fig. 24: Optical photograph of F24 
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Fig. 25: Optical photograph of F25 Fig. 26: Optical photograph of F26 Fig. 27: Optical photograph of F27 
 
Fig. 28: Optical photograph of F28 
  
   
Fig. 29: TEM photograph of F1 Fig. 30: TEM photograph of F2 Fig. 31: TEM photograph of F3 
   
Fig. 32: TEM photograph of F4 Fig. 33: TEM photograph of F5 Fig. 34: TEM photograph of F6 
   
Fig. 35: TEM photograph of F7 Fig. 36: TEM photograph of F8 Fig. 37: TEM photograph of F9 
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Fig. 38: TEM photograph of F10 Fig. 39: TEM photograph of F11 Fig. 40: TEM photograph of F12 
   
Fig. 41: TEM photograph of F13 Fig. 42: TEM photograph of F14 Fig. 43: TEM photograph of F15 
   
Fig. 44: TEM photograph of F16 Fig. 45: TEM photograph of F17 Fig. 46: TEM photograph of F18 
   
Fig. 47: TEM photograph of F19 Fig. 48: TEM photograph of F20 Fig. 49: TEM photograph of F21 
   
Fig. 50: TEM photograph of F22 Fig. 51: TEM photograph of F23 Fig. 52: TEM photograph of F24 
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Fig. 53: TEM photograph of F25 Fig. 54: TEM photograph of F26 Fig. 55: TEM photograph of F27 
 
Fig. 56: TEM photograph of F28 
 
Morphological characterization using TEM 
Vesicles formation was further confirmed by TEM. The 
transmission electron microscopy photographs of the niosomes 
prepared from proniosomal formulae are shown in fig. (29-56). 
From the presented figures, it is apparent that the majority of 
the vesicles are well identified, nanosized and separate with 
sharp outermost bilayer boundaries having large internal space. 
The vesicles seem to be like a spherical reservoir and devoid of 
any surface artifacts. 
Analysis of the recorded TEM images 
Analysis of TEM photographs of all proniosomal formulae using the 
software Nano Measurer 1.2.5 revealed that the mean particle size of all 
prepared formulae ranged between 142.98 nm (F13) and 861.98 nm 
(F15) as presented in fig. (57-84). The discussion of particle size analysis 
results here is illogical as TEM images represent a very small section of 
the sample so full discussion of particle size analysis will be in the next 
test. We just took an overview about particle size distribution of all 
prepared formulae. 
 
   
Fig. 57: Size distribution of F1 Fig. 58: Size distribution of F2 Fig. 59: Size distribution of F3 
   
Fig. 60: Size distribution of F4 Fig. 61: Size distribution of F5 Fig. 62: Size distribution of F6 
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Fig. 63: Size distribution of F7 Fig. 64: Size distribution of F8 Fig. 65: Size distribution of F9 
   
Fig. 66: Size distribution of F10 Fig. 67: Size distribution of F11 Fig. 68: Size distribution of F12 
   
Fig. 69: Size distribution of F13 Fig. 70: Size distribution of F14 Fig. 71: Size distribution of F15 
   
Fig. 72: Size distribution of F16 Fig. 73: Size distribution of F17 Fig. 74: Size distribution of F18 
   
Fig. 75: Size distribution of F19 Fig. 76: Size distribution of F20 Fig. 77: Size distribution of F21 
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Fig. 78: Size distribution of F22 Fig. 79: Size distribution of F23 Fig. 80: Size distribution of F24 
   
Fig. 81: Size distribution of F25 Fig. 82: Size distribution of F26 Fig. 83: Size distribution of F27 
 
Fig. 84: Size distribution of F28 
 
Particle size analysis and PDI determination 
Vesicles size and particle size distribution are important parameters 
for the vesicular drug delivery systems. The particle size of the 
formed vesicles was in the nanometric dimensions ranging from 
252.9±0.43 nm (F4) to 624.3±0.23 nm (F28) as seen in the table (3). 
From the particle size analysis, it was clear that there are two factors 
affecting particle size which are surfactant type and cholesterol 
content. There was an increment in the vesicular size upon 
increasing the alkyl chain length of surfactant. The size of the vesicles 
increased gradually from span 20 (252.9±0.43–357.2±0.56 nm) <span 
40 (361.7±0.84–419.1±1.05 nm) <span 60 (428.2±0.74–494.6±0.51 
nm)<span 80 (512.4±0.47-624.3±0.23 nm). This increment is linked 
to the alkyl chain length of span (C12-C18), which leads to elevated 
critical packing parameter thus the vesicle size increases [36]. It was 
also observed as the cholesterol concentration increased, an 
increase in the mean vesicle size occurred. This comes in accordance 
with the research done by Manconi et al. [37], who noted that, as the 
cholesterol surfactant ratio decreased in niosomal formulae, 
reduction in the vesicle size occur. The structure properties of 
cholesterol and its lipid solubility are the cause for its effect on the 
vesicle size. Cholestrol is loaded in hollow spaces between the 
surfactant molecules and expands the vesicles bilayers thus 
increased the particle size of vesicles [38]. It was also noticed that 
small sized vesicles with high surface charge values formed when 
the equal molar ratio of surfactant and cholesterol were used as 
presented in table (3). Our results also comply with the literature 
reports [39]. The mean particle size is not the only parameter to be 
considered in the formulation of proniosomes. The size distribution 
is another parameter of equal importance. The polydispersity index 
was calculated according to Bhavana et al. [40]. A polydispersity 
index of 1 indicates large variations in particle size; a reported value 
of 0 means that size variation is absent [41]. The obtained low PDI 
values of all proniosomes derived niosomes (0.387±0.05–
0.835±0.03) indicate a limited variation in particle size as reported 
in the table (3).  
Zeta potential determination 
Zeta potential predicts the stability of the carrier system. The higher 
the zeta potential value, the more repulsion between charged 
particles and hence the more stability against aggregation. Particles 
with zeta potential values more than (+30 mV) or less than (-30 mV) 
are considered stable [42]. The zeta potential values of all prepared 
proniosomal formulae are listed in table (3). The values ranged from 
between-18.3±0.56 to-43.8±0.35 mV which are high enough for 
electrostatic stabilization. Negative values of all prepared formulae 
indicate the formation of stable systems [43]. This higher charge on 
the vesicle surfaces produces a repulsion force which made them 
stable, devoid of aggregation and providing an evenly distributed 
dispersion. These results were in complete accordance with Litha et 
al. who prepared Clotrimazole based proniosomes, and found that 
zeta potential of the optimized formula was-44.45 mV [44]. 
Stability studies 
Based upon the rank order employed for all proniosomal formulae 
depending on their characterization, two optimized proniosomal 
formulae were selected to be tested for stability study. From the 
particle size analysis, zeta potential and micromeritic properties, 
formulae F11 and F9 were chosen respectively as illustrated in table 
(4). The physical appearance, micromeritic properties, vesicle size 
and zeta potential were monitored for the optimized proniosomal 
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powder formulae F9 and F11 upon storage at refrigerated and 
ambient room temperature for a period of 90 d as shown in the table 
(5). The results indicated that there was no appreciable change in 
physical appearance, flow characteristics and zeta potential when 
formulae F9 and F11 were stored at refrigerated and room 
temperatures. However, there was a slight increase in vesicle size of 
the prepared formulae. This increase was higher in formulae stored 
at room temperature than at refrigerated temperature indicating 
that prepared formulae were relatively stable at 4±1 °C, as 
compared to 25 °C±2. The stability studies suggest that the 
proniosomal formulae were comparatively more stable when stored 
at refrigerated conditions compared to room temperature. 
 
Table 3: Particle size, PDI and zeta potential of all prepared proniosomal formulae 
Formula Particle size* PDI (nm) Zeta potential* * (mV) 
F1 308.0±0.25 0.387±0.05 -40.4±0.87 
F2 298.8±0.74 0.835±0.03 -40.8±1.17 
F3 264.6±0.50 0.505±0.08 -41.2±0.45 
F4 252.9±0.43 0.591±0.11 -42.3±0.71 
F5 330.3±0.14 0.432±0.19 -39.0±0.09 
F6 357.2±0.56 0.477±0.04 -36.4±0.24 
F7 338.2±0.33 0.596±0.02 -28.4±0.17 
F8 366.8±0.61 0.610±0.14 -41.4±0.61 
F9 365.9±0.17 0.411±0.02 -43.8±0.35 
F10 361.7±0.84 0.626±0.09 -43.4±0.26 
F11 396.9±1.14 0.431±0.06 -41.4±0.44 
F12 410.4±0.27 0.444±0.04 -42.6±1.12 
F13 386.7±0.83 0.678±0.05 -39.0±0.28 
F14 419.1±1.05 0.403±0.12 -39.5±0.33 
F15 448.3±0.44 0.433±0.07 -30.3±0.49 
F16 433.9±0.65 0.605±0.14 -22.2±0.39 
F17 446.8±0.37 0.410±0.16 -38.4±0.75 
F18 428.2±0.74 0.416±0.08 -28.6±0.14 
F19 455.5±0.41 0.460±0.06 -24.3±0.42 
F20 494.6±0.58 0.652±0.20 -22.1±0.39 
F21 470.8±0.29 0.409±0.04 -23.1±1.04 
F22 512.4±0.47 0.630±0.13 -18.3±0.56 
F23 554.5±0.95 0.469±0.07 -24.6±0.27 
F24 541.8±0.71 0.487±0.11 -36.9±0.08 
F25 518.7±0.18 0.478±0.08 -22.0±0.15 
F26 558.7±0.53 0.526±0.09 -24.6±0.47 
F27 622.0±0.88 0.540±0.14 -23.1±1.09 
F28 624.3±0.23 0.512±0.03 -24.5±0.24 
*Results are expressed as mean±SD, n=3 
 
Table 4: Rank order of all proniosomal formulae according to particle size analysis, zeta potential and micromeritic properties 








Total rank order Conclusive rank 
order 
F1 4 1 28 15 48 10 
F2 3 9 23 17 52 12 
F3 2 8 27 23 60 17 
F4 1 5 20 26 52 12 
F5 5 11 22 22 60 17 
F6 7 15 16 21 59 16 
F7 6 18 15 24 63 21 
F8 10 6 14 6 36 5 
F9 9 2 12 5 28 2 
F10 8 3 10 8 29 3 
F11 12 6 6 3 27 1 
F12 13 4 11 12 40 8 
F13 11 11 3 14 39 7 
F14 14 10 5 7 36 5 
F15 18 16 8 11 53 14 
F16 16 25 9 10 60 17 
F17 17 13 2 2 34 4 
F18 15 17 12 3 47 9 
F19 19 22 4 8 53 14 
F20 21 26 1 1 49 11 
F21 20 23 6 13 62 20 
F22 22 28 25 28 103 28 
F23 25 19 26 25 95 27 
F24 24 14 24 27 89 26 
F25 23 27 17 19 86 24 
F26 26 19 21 18 84 22 
F27 27 23 18 16 84 22 
F28 28 21 19 20 88 25 
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Table 5: Effect of storage on micromeritic properties, vesicle size and zeta potential of proniosomal formulae F9 and F11 at room and 
refrigeration temperatures 
 Time (Day) F9  F11 
4 °C 25 °C 4 °C 25 °C 
Angle  
of  repose* 
0 27.34±0.71 26.69±0.24 
30 28.87±0.33 27.11±0.58 26.47±0.67 27.18±0.89 
60 28.55±0.94 28.68±0.24 28.35±0.38 30.87±0.08 
90 27.39±0.57 30.22±0.84 27.59±0.42 32.15±0.14 
Carr’s index*  
(%)  
0 13.24±1.04 12.81±0.81 
30 14.74±0.61 13.87±1.29 14.55±0.72 13.31±0.48 
60 13.08±0.37 15.49±0.78 14.17±0.35 15.94±0.15 
90 13.54±0.88 17.32±0.26 13.31±0.41 16.28±1.14 
Hausner ratio* 0 1.20± 1.19± 
30 1.21±0.06 1.22±0.04 1.22±0.02 1.18±0.01 
60 1.14±0.09 1.24±0.06 1.18±0.05 1.21±0.05 
90 1.18±0.02 1.27±0.03 1.17±0.01 1.24±0.07 
Vesicle size* 
(nm) 
0 320.70±1.94 375.84±2.04 
30 335±1.23 357±2.14 394±1.22 438±0.87 
60 327±0.84 384±0.53 405±2.37 429±1.69 
90 348±1.57 387±0.71 416±1.90 433±2.08 
Zeta potential* 
(mV) 
0 -42.7±0.64 -40.1±1.23 
30 -40.5±1.06 -39.5±0.32 -41.5±0.29 -39.4±0.58 
60 -41.3±0.48 -40.7±1.29 -40.3±0.67 -35.3±1.84 
90 -38.2±1.59 -36.4±0.81 -40.7±1.39 -37.7±0.79 
*Results are expressed as mean±SD, n=3 
 
CONCLUSION 
The unloaded prepared vesicular systems were found to fulfill the 
characteristics of proniosomes. They had a particle size in the 
nanometric range, negative high zeta potential values as well as 
good flow characters. The optimized proniosomal formula 
containing span 40 and cholesterol in equimolar ratio exhibited low 
size, high surface charge, and good flow properties. The obtained 
results offered evidence that spray-dried lactose based proniosomes 
are promising stable drug delivery carriers and ready to incorporate 
different poorly water-soluble drugs in order to improve their 
limited oral bioavailability.  
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